INTERVIEWING

Quote






anonymous said:
Script totals pay for maybe 2 or 3 reps salaries, Merck pulled out of the market because sales were so bad and they maybe have 1 year left before Stallergenes decides to pull the plug. So I would say that the poster wasn't dramatic enough.
Click to expand...

No chance that they will last another year. Before June this will be shut down
 






Can't really disagree with any of the negative comments I'm seeing here about Greer. So to anyone at Greer now or looking to interview, here's my opinion...

Current Employees: Find another place to go or at the very least be prepared for the hammer because short of adding another product, this is it. Once enough relevant data is in though March and they can forecast the season, everyone is gone. Last years goal 3 million, trending to 1.3 million and 2017 goal of 5.2 million? When you are 47% to goal for 2016 and in 2017 you probably won't come close to the 3 million that was set for the previous year...products go back on the shelf.

Candidates: If you are currently working but hate where you are, stay put and find somewhere else besides Greer. If you are unemployed and have anything remotely possible, don't sign on at Greer, wait it out as you don't want to potentially get stuck in a non compete. Now if you are unemployed and are willing only to take a job to add things to your resume like calling on specialists, specialty pharmacy experience, etc. then take the money and continue looking for another job elsewhere and jump the moment you can. So bottomline, if you can pay your bills by legal means, don't even interview.

This is about as unbiased as it get as I am not a disgruntled ex-employee. I'm a current employee who is simply realistic about what is going on in our company. Now it's about finding the right job outside of Greer as most of left jobs of 10-15 years experience to come here for 1 or 2 years and don't want to make the wrong move again. But it's beginning to look like any move at this point would be the better move.
 






While I don't disagree in principle regarding the shit show that is Greer, there are multitudes of slimy career pharma types that have assembled in Cambridge that will spin this disaster 15 different ways to keep getting their crooked pockets lined. Sales results according to analysts (who were told this by Greer and Merck) for grass tablets was supposed to approach $1 Billion. And now the goal which will be missed horribly is $5 Million???? What the hell is wrong with the parent company to keep throwing more money at this charade?
 






anonymous said:
While I don't disagree in principle regarding the shit show that is Greer, there are multitudes of slimy career pharma types that have assembled in Cambridge that will spin this disaster 15 different ways to keep getting their crooked pockets lined. Sales results according to analysts (who were told this by Greer and Merck) for grass tablets was supposed to approach $1 Billion. And now the goal which will be missed horribly is $5 Million???? What the hell is wrong with the parent company to keep throwing more money at this charade?
Click to expand...
The number is nowhere near 5 million. Can anyone think of another drug in the pharma world that has cost a company so much money and only produced less than 2 million?
 






anonymous said:
The number is nowhere near 5 million. Can anyone think of another drug in the pharma world that has cost a company so much money and only produced less than 2 million?
Click to expand...

Semantics, but yes...I can, all those products that cost 100 to 150 million to get smacked by the FDA an never come to market. For a company the size of Greer it doesn't need to be a Billion Dollar market. That's Greer's biggest problem. They lack transparency. Just be honest. Greer has leadership in Allergy Immunotherapy from an extract perspective. Oralair is/was supposed to be the golden ticket into Specialty and PCPs with other products. Oralair's SalesForce was supposed to show it was worthy of a partnership or bringing in another product backed by other investors if necessary. STAGR has not done that unless you count a recent 50 million dollar line of credit and the recent Stanford deal.

In the US there is only Grass right now, and HDM and possibly tree and even genetic testing for which patients will do well with respect to nut allergies is a few or more years off. It's been said a million times...something needs to happen within months because there is no way this Sales Force lasts long enough for HDM or any other "Pipeline" product. And seriously, ALK has their HDM drug studied and presented to the FDA already and we haven't even enrolled our final patients, despite the fact we have data and indications overseas. It's pretty much an indictment on how the US affiliate is being run combined with just a lack of SLIT opportunity in the US.
 






All true, the real question is why are they still throwing good money after bad? Admit you were lied to and sold a sack of crap, then take your tax write off and move on. This place just gets worse month after month and all they do is hire more idiots in Boston.
 












Top Bottom
Back
Quote